JP Morgan Chase’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-176,956
| Closed | -$1.7M | – | 7881 |
|
|
2024
Q4 | $1.7M | Buy |
176,956
+114,008
| +181% | +$595K | ﹤0.01% | 4273 |
|
|
2024
Q3 | $180K | Buy |
62,948
+32,785
| +109% | +$101K | ﹤0.01% | 5458 |
|
|
2024
Q2 | $88.1K | Sell |
30,163
-48,362
| -62% | -$132K | ﹤0.01% | 5590 |
|
|
2024
Q1 | $250K | Buy |
78,525
+32,402
| +70% | +$108K | ﹤0.01% | 5226 |
|
|
2023
Q4 | $155K | Sell |
46,123
-16,770
| -27% | -$43.2K | ﹤0.01% | 5522 |
|
|
2023
Q3 | $150K | Buy |
62,893
+5,458
| +10% | +$11.4K | ﹤0.01% | 5242 |
|
|
2023
Q2 | $101K | Buy |
57,435
+55,686
| +3,184% | +$142K | ﹤0.01% | 5457 |
|
|
2023
Q1 | $6K | Sell |
1,749
-29,475
| -94% | -$177K | ﹤0.01% | 6224 |
|
|
2022
Q4 | $165K | Sell |
31,224
-81,963
| -72% | -$375K | ﹤0.01% | 5132 |
|
|
2022
Q3 | $400K | Sell |
113,187
-120,997
| -52% | -$400K | ﹤0.01% | 4595 |
|
|
2022
Q2 | $604K | Sell |
234,184
-84,492
| -27% | -$235K | ﹤0.01% | 4441 |
|
|
2022
Q1 | $1.43M | Buy |
318,676
+20,894
| +7% | +$94.2K | ﹤0.01% | 4018 |
|
|
2021
Q4 | $2.03M | Sell |
297,782
-56,283
| -16% | -$383K | ﹤0.01% | 3848 |
|
|
2021
Q3 | $2.58M | Buy |
354,065
+41,371
| +13% | +$355K | ﹤0.01% | 3572 |
|
|
2021
Q2 | $3.13M | Buy |
312,694
+1,832
| +0.6% | +$16.4K | ﹤0.01% | 3445 |
|
|
2021
Q1 | $2.97M | Buy |
310,862
+304,917
| +5,129% | +$2.99M | ﹤0.01% | 3405 |
|
|
2020
Q4 | $65K | Buy |
5,945
+939
| +19% | +$9.9K | ﹤0.01% | 5097 |
|
|
2020
Q3 | $45K | Buy |
+5,006
| New | +$57K | ﹤0.01% | 4971 |
|
Other funds holding PSTX
JP Morgan Chase's PSTX Position: Q1 2025 in Review
JP Morgan Chase sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 176,956 shares — an estimated $1.7M sold.
JP Morgan Chase first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $3.13M in Q2 2021. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- JP Morgan Chase reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- JP Morgan Chase sold 176,956 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.7M.
- JP Morgan Chase first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- JP Morgan Chase's Poseida Therapeutics, Inc. Common Stock position peaked at $3.13M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.